Atogepant, a medication for migraines, performs better than Rimegepant in a matching-adjusted indirect comparison analysis.

Published Date: 22 Jun 2023

Even though there was no statistically significant difference in treatment-emergent adverse events or all-cause discontinuation, the atogepant 60 mg once daily group experienced significantly larger decreases in mean monthly migraine days across weeks 1–12 and weeks 9–12.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot